Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.05 (-7.21%)
Close on Nov 17, 2026Market cap $23.84MP/E –Yield –
Metagenomi Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Metagenomi Therapeutics's price to book ratio was 0.3× on Nov 11, 2026, against 0.4× a year earlier. Over the last 3 years it ranged from 0.2× to 0.9×, with a median of 0.3×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.3× | −0.1 |
| 2025 | Dec 31, 2025 | 0.3× | −0.2 |
| 2024 | Dec 31, 2024 | 0.5× | – |
See a number that looks wrong?